OverviewSuggest Edit

Sprint Bioscience is a pharmaceutical company focused on developing drugs to fight cancer. It runs pharmaceutical projects from conception to drug candidates ready for clinical trials. Sprint Bioscience's portfolio of projects is focused on exploiting metabolic pathways for the treatment of cancer. Additionally, the company develops a program for type 2 diabetes.

TypePublic
Founded2009
Websitesprintbioscience.com

Latest Updates

Employees (est.) (Jul 2021)33(+18%)
Share Price (Sept 2021)KR4.7
Cybersecurity ratingAMore

Key People/Management at Sprint Bioscience

Rune Nordlander

Rune Nordlander

Board Member
Jessica Martinsson

Jessica Martinsson

COO
Erik Kinnman

Erik Kinnman

CEO
Martin Andersson

Martin Andersson

Cheif Scientific Officer
Anne-Marie Wenthzel

Anne-Marie Wenthzel

Cheif Business Officer
Show more

Sprint Bioscience Financials and Metrics

Sprint Bioscience Revenue

Market capitalization (17-Sept-2021)

99.9m

Closing stock price (17-Sept-2021)

4.7
Sprint Bioscience's current market capitalization is kr99.9 m.
Show all financial metrics

Sprint Bioscience Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Sprint Bioscience Online and Social Media Presence

Embed Graph

Sprint Bioscience Blogs

BioStock: A new cancer project in Sprint Bioscience’s portfolio

In connection with the rights issue this summer, the biotechnology company Sprint Bioscience promised further investments in expanding the development portfolio. Now, about a week after completing the issue, the company has announced NIMA, a cancer project that targets a tumour’s microenvironment to…

Sprint Bioscience adds new cancer drug program to its project portfolio

Sprint Bioscience AB (publ) announces today that the company is broadening its pipeline with an additional drug program for the treatment of solid tumors. The program goes by the program name NIMA and aims to develop drugs to inhibit a naturally occurring protein that is associated with poor surviva…

Sprint Bioscience licenses the cancer drug program Vps34 to Deciphera Pharmaceuticals

Sprint Bioscience AB (publ) announces today that the company has licensed its cancer drug program Vps34 to the US pharmaceutical company Deciphera Pharmaceuticals. The license agreement covers exclusive global rights to the program. The agreement has a total potential value of up to USD 277 million,…

14-18 June 2021: BIO International Convention DIGITAL

For the second year, the BIO International Convention is being held digitally. This is the world’s largest partnership event for the Life Science industry and the participants’ will network to discuss licensing deals and research collaborations. The Sprint Bioscience team will both meet representati…

Presentation from BioStock Life Science Summit, May, 2021

Sprint Bioscience CEO, Erik Kinnman, presented the company at the digital spring edition of the BioStock Life Science Summit on May 27th, 2021.

26-27 maj 2021: BioStock Life Science Summit

Sprint Bioscience CEO Erik Kinnman will present the company at the digital spring edition of the BioStock Life Science Summit. The meeting includes company presentations as well as panel discussions and will be filmed and streamed via Youtube. More information will be available here.
Show more

Sprint Bioscience Frequently Asked Questions

  • When was Sprint Bioscience founded?

    Sprint Bioscience was founded in 2009.

  • Who are Sprint Bioscience key executives?

    Sprint Bioscience's key executives are Rune Nordlander, Jessica Martinsson and Erik Kinnman.

  • How many employees does Sprint Bioscience have?

    Sprint Bioscience has 33 employees.

  • Who are Sprint Bioscience competitors?

    Competitors of Sprint Bioscience include Italfarmaco, Ascentage Pharma and Janssen Pharmaceuticals.